Among patients treated with tPA for acute ischaemic stroke, those aged ≥80 years had a similar risk of symptomatic intracerebral haemorrhage compared to those <80 years (4.4% vs 4.6%; p=1.0).
Cohort (n=1,135)
Yes
Does intravenous tPA treatment in acute ischaemic stroke patients aged ≥80 years have similar safety and efficacy compared to patients aged <80 years?
In carefully selected patients aged ≥80 years with acute ischemic stroke, intravenous tPA is not associated with an increased risk of symptomatic intracerebral hemorrhage compared to younger patients, despite a lower rate of favorable functional outcomes.
Absolute Event Rate: 4.4% vs 4.6%
p-value: p=1.0
BACKGROUND: The benefit of intravenous tissue plasminogen activator (tPA) given within 3 h of acute ischaemic stroke to patients over 80 years of age is uncertain. AIM: To examine the clinical characteristics and complications and the predictors of outcome after intravenous tPA treatment in patients aged > or = 80 years. METHODS: Data (n = 1135) prospectively collected from the Canadian Alteplase for Stroke Effectiveness Study were reviewed and patients aged > or = 80 years (n = 270) treated with intravenous tPA for acute ischaemic stroke were compared with those aged or = 80 years and or = 80 years and in 40% of those or = 80 years than in those aged or = 80 years, stroke severity, baseline Alberta Stroke Program Early CT Score and glucose level were found to be the major independent predictors of outcome. CONCLUSION: In carefully selected elderly patients, the use of intravenous tPA was not found to be associated with an increased risk of symptomatic intracerebral haemorrhage. Age-related differences were seen in the clinical characteristics and outcome in the elderly population.
PN Sylaja (Tue,) conducted a cohort in acute ischaemic stroke (n=1,135). Age ≥ 80 years (receiving intravenous tPA) vs. Age < 80 years was evaluated on symptomatic intracerebral haemorrhage (p=1.0). Among patients treated with tPA for acute ischaemic stroke, those aged ≥80 years had a similar risk of symptomatic intracerebral haemorrhage compared to those <80 years (4.4% vs 4.6%; p=1.0).